Contact
searchSearch
HMP Global
Login

Videos

Geoffrey Ku, MD
Videos
Zanidatamab-Based Regimens Redefine First-Line Treatment of HER2-Positive Gastroesophageal Adenocarcinoma
09/08/2026
Geoffrey Ku, MD
Geoffrey Ku, MD, discusses findings from the phase 3 HERIZON-GEA-01 trial evaluating first-line zanidatamab plus chemotherapy, with or without tislelizumab, in patients with HER2-positive gastroesophageal adenocarcinoma, highlighting improved...
Geoffrey Ku, MD, discusses findings from the phase 3 HERIZON-GEA-01 trial evaluating first-line zanidatamab plus chemotherapy, with or without tislelizumab, in patients with HER2-positive gastroesophageal adenocarcinoma, highlighting improved...
Geoffrey Ku, MD, discusses...
09/08/2026
Oncology
Viktor Grünwald, MD, PhD
Videos
Nivolumab Plus Ipilimumab Fails to Overcome Immunotherapy Resistance in Head and Neck Squamous Cell Carcinoma
09/02/2026
Viktor Grünwald, MD, PhD
Viktor Grünwald, MD, PhD, discusses results from the phase 2 OPTIM study evaluating nivolumab plus ipilimumab versus docetaxel after failure to respond to nivolumab in head and neck cancer, highlighting the need for novel strategies to...
Viktor Grünwald, MD, PhD, discusses results from the phase 2 OPTIM study evaluating nivolumab plus ipilimumab versus docetaxel after failure to respond to nivolumab in head and neck cancer, highlighting the need for novel strategies to...
Viktor Grünwald, MD, PhD,...
09/02/2026
Oncology
Allen Khudaverdyan, MD
Videos
Statin-Specific Effects May Influence Immunotherapy Outcomes in Patients With Head and Neck Squamous Cell Carcinoma
09/02/2026
Allen Khudaverdyan, MD
Allen Khudaverdyan, MD, discusses results from a large retrospective study evaluating concurrent statin use in patients with head and neck squamous cell carcinoma receiving immune checkpoint inhibitors, highlighting statin-specific survival...
Allen Khudaverdyan, MD, discusses results from a large retrospective study evaluating concurrent statin use in patients with head and neck squamous cell carcinoma receiving immune checkpoint inhibitors, highlighting statin-specific survival...
Allen Khudaverdyan, MD,...
09/02/2026
Oncology
Christopher Noel, MD, PhD
Videos
Perioperative Pembrolizumab May Not Be Cost-Effective in Advanced Head and Neck Cancer
09/02/2026
Christopher Noel, MD, PhD
Christopher Noel, MD, PhD, discusses a cost-effectiveness analysis of perioperative pembrolizumab in locally advanced head and neck cancer, highlighting how current drug pricing and treatment duration may limit cost-effectiveness despite the...
Christopher Noel, MD, PhD, discusses a cost-effectiveness analysis of perioperative pembrolizumab in locally advanced head and neck cancer, highlighting how current drug pricing and treatment duration may limit cost-effectiveness despite the...
Christopher Noel, MD, PhD,...
09/02/2026
Oncology

Recent News

FDA Approval
FDA Expands Sevabertinib Approval to First-Line HER2-Mutant Advanced Non-Small Cell Lung Cancer
09/09/2026
Stephanie Holland
The FDA expanded the accelerated approval of sevabertinib to adults with locally advanced or metastatic non-squamous non-small cell lung cancer harboring HER2 activating mutations, extending the targeted therapy into the first-line setting...
The FDA expanded the accelerated approval of sevabertinib to adults with locally advanced or metastatic non-squamous non-small cell lung cancer harboring HER2 activating mutations, extending the targeted therapy into the first-line setting...
The FDA expanded the accelerated...
09/09/2026
Oncology
FDA Approval
FDA Approves Camizestrant Plus CDK4/6 Inhibitor Following Emergence of ESR1 Mutation in Advanced Breast Cancer
09/08/2026
Emily Estrada
Based on results from the phase 3 SERENA-6 trial, the FDA granted accelerated approval to camizestrant plus a CDK4/6 inhibitor for HR-positive, HER2-negative advanced breast cancer following detection of an ESR1 mutation during ongoing...
Based on results from the phase 3 SERENA-6 trial, the FDA granted accelerated approval to camizestrant plus a CDK4/6 inhibitor for HR-positive, HER2-negative advanced breast cancer following detection of an ESR1 mutation during ongoing...
Based on results from the phase...
09/08/2026
Oncology
News
Early-Phase Data Support Further Evaluation of Daraxonrasib in RAS-Mutant Non-Small Cell Lung Cancer
09/03/2026
Stephanie Holland
Early-phase results showed that daraxonrasib produced meaningful antitumor activity across dose levels in previously treated advanced RAS-mutant non–small cell lung cancer, supporting further evaluation of this oral RAS(ON) multiselective...
Early-phase results showed that daraxonrasib produced meaningful antitumor activity across dose levels in previously treated advanced RAS-mutant non–small cell lung cancer, supporting further evaluation of this oral RAS(ON) multiselective...
Early-phase results showed that...
09/03/2026
Oncology
News
Etentamig Significantly Reduces Risk of Progression or Death in Triple-Class Exposed Relapsed or Refractory Multiple Myeloma
09/03/2026
Stephanie Holland
Topline results from the phase 3 CERVINO trial showed that etentamig significantly improved response and progression-free survival over standard available therapies in triple-class exposed relapsed or refractory multiple myeloma, supporting...
Topline results from the phase 3 CERVINO trial showed that etentamig significantly improved response and progression-free survival over standard available therapies in triple-class exposed relapsed or refractory multiple myeloma, supporting...
Topline results from the phase 3...
09/03/2026
Oncology
News
Ivonescimab Plus Chemotherapy Improves Progression-Free Survival in EGFR-Mutated Non-Small Cell Lung Cancer
09/02/2026
Stephanie Holland
Results from the phase 3 HARMONi trial showed that ivonescimab plus chemotherapy improved progression-free survival compared with chemotherapy alone in patients with advanced EGFR-mutated NSCLC after progression on third-generation EGFR...
Results from the phase 3 HARMONi trial showed that ivonescimab plus chemotherapy improved progression-free survival compared with chemotherapy alone in patients with advanced EGFR-mutated NSCLC after progression on third-generation EGFR...
Results from the phase 3 HARMONi...
09/02/2026
Oncology
News
Longer Follow-Up Reinforces Clinical Benefit of Perioperative Durvalumab in Resectable Non-Small Cell Lung Cancer
09/02/2026
Stephanie Holland
Updated results from the phase 3 AEGEAN trial showed that perioperative durvalumab plus neoadjuvant chemotherapy maintained an event-free survival benefit compared with neoadjuvant chemotherapy alone in patients with resectable non-small cell...
Updated results from the phase 3 AEGEAN trial showed that perioperative durvalumab plus neoadjuvant chemotherapy maintained an event-free survival benefit compared with neoadjuvant chemotherapy alone in patients with resectable non-small cell...
Updated results from the phase 3...
09/02/2026
Oncology
News
Perioperative Pembrolizumab Nearly Doubles 5-Year Event-Free Survival in Patients With Resectable Non-Small Cell Lung Cancer
09/01/2026
Stephanie Holland
Five-year results from the phase 3 KEYNOTE-671 trial showed that perioperative pembrolizumab plus neoadjuvant chemotherapy provided durable event-free and overall survival benefits compared with neoadjuvant chemotherapy and surgery alone in...
Five-year results from the phase 3 KEYNOTE-671 trial showed that perioperative pembrolizumab plus neoadjuvant chemotherapy provided durable event-free and overall survival benefits compared with neoadjuvant chemotherapy and surgery alone in...
Five-year results from the phase...
09/01/2026
Oncology
News
NEO100-01 Meets Primary End Point, Supporting Further Development in IDH1-Mutant Glioma
08/31/2026
Emily Estrada
Topline results from the phase 2a NEO100-01 trial showed that intranasal NEO100 achieved a 48.9% 6-month progression-free survival rate in patients with recurrent IDH1-mutant high-grade glioma, significantly exceeding the prespecified 20%...
Topline results from the phase 2a NEO100-01 trial showed that intranasal NEO100 achieved a 48.9% 6-month progression-free survival rate in patients with recurrent IDH1-mutant high-grade glioma, significantly exceeding the prespecified 20%...
Topline results from the phase...
08/31/2026
Oncology
News
Zanidatamab Plus Chemotherapy Improves Overall Survival in HER2-Positive Advanced Gastroesophageal Adenocarcinoma
08/31/2026
Stephanie Holland
Updated phase 3 HERIZON-GEA-01 results showed that zanidatamab-based regimens improved overall survival compared with trastuzumab plus chemotherapy in first-line HER2-positive advanced gastroesophageal adenocarcinoma, strengthening the...
Updated phase 3 HERIZON-GEA-01 results showed that zanidatamab-based regimens improved overall survival compared with trastuzumab plus chemotherapy in first-line HER2-positive advanced gastroesophageal adenocarcinoma, strengthening the...
Updated phase 3 HERIZON-GEA-01...
08/31/2026
Oncology
News
Real-World Study Shows Nirogacestat Provides Sustained Disease Control and Symptom Improvement in Patients With Desmoid Tumors
08/31/2026
Emily Estrada
A real-world study of nirogacestat in patients with desmoid tumors demonstrated durable disease control, tumor responses, and meaningful pain improvement, with many patients also reducing or discontinuing analgesics, reinforcing the clinical...
A real-world study of nirogacestat in patients with desmoid tumors demonstrated durable disease control, tumor responses, and meaningful pain improvement, with many patients also reducing or discontinuing analgesics, reinforcing the clinical...
A real-world study of...
08/31/2026
Oncology

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use